13 min.
Discussing Rheumatology: April 2023 The IMID Forum
-
- Onderwijs
Join Prof Iain McInnes as he reviews two interesting papers that help to broaden our understanding and knowledge on the safety of biologic and targeted synthetic DMARDs.
In the first of today’s papers, Matthew Baker and colleagues determine the risk of developing interstitial lung disease (ILD) in patients with RA, undergoing treatment with different biologic and targeted synthetic DMARDs.
In the second paper, Lars Kristensen and team analyse data from ORAL Surveillance to help identify subpopulations with different relative risk (i.e., ’high-risk’ and ’low-risk’) with tofacitinib versus TNFi.
To access detailed summary slides of the papers discussed today, visit cytokinesignalling.com.
Join Prof Iain McInnes as he reviews two interesting papers that help to broaden our understanding and knowledge on the safety of biologic and targeted synthetic DMARDs.
In the first of today’s papers, Matthew Baker and colleagues determine the risk of developing interstitial lung disease (ILD) in patients with RA, undergoing treatment with different biologic and targeted synthetic DMARDs.
In the second paper, Lars Kristensen and team analyse data from ORAL Surveillance to help identify subpopulations with different relative risk (i.e., ’high-risk’ and ’low-risk’) with tofacitinib versus TNFi.
To access detailed summary slides of the papers discussed today, visit cytokinesignalling.com.
13 min.